Loading market dashboard
WW International, Inc.
WWConsumer CyclicalNASDAQUS
Loading disclosure news
News and disclosures filtered by period, publisher, and event group.
Select a headline to open the full news page in the app.
NEW YORK, June 04, 2026 (GLOBE NEWSWIRE) -- WW International, Inc. (NASDAQ: WW) and its affiliated medical groups (“Weight Watchers”), the global leader in science-backed weight management, is now accessible via Eli Lilly and Company's digital healthcare platform, LillyDirect®. This news further reflects Weight Watchers' continued focus on expanding access to trusted, brand-name GLP-1 medications paired with comprehensive clinical and behavioral support, designed for real life.
NEW YORK--(BUSINESS WIRE)--Galloway Capital Partners, LLC (“Galloway”), together with its affiliates, today announced that it has accumulated an ownership stake of approximately 8.42% in WW International, Inc. (“WW” or the “Company”). Galloway believes WW is materially undervalued despite owning one of the world's most recognized wellness brands and operating in the rapidly growing markets of weight management, metabolic health, GLP-1 support, and longevity. Following its recent restructuring,.
WW International, Inc. (WW) Q1 2026 Earnings Call Transcript
WW International NASDAQ: WW, operator of WeightWatchers, reaffirmed its 2026 financial outlook after reporting first-quarter results that reflected continued pressure in its legacy behavioral subscription business, offset in part by growth in its clinical weight-management offering and higher-value membership tiers.
WW International posted lower revenue in the first quarter, as behavioral subscription sales fell.
Total End of Period Subscribers of 2.7 million; End of Period Clinical Subscribers of 197 thousand, up 46% year-over-year Revenue of $168 million; Clinical Subscription Revenue of $39 million, up 32% year-over-year Reaffirms Full Year 2026 Financial Guidance Announces Fully Subscribed Debt Prepayment Solicitation as Part of Actions Expected to Reduce Debt by $42 Million NEW YORK, May 07, 2026 (GLOBE NEWSWIRE) -- WW International, Inc. (Nasdaq: WW) (“Weight Watchers” or the “Company”), the global leader in science-backed weight management, today announced its results for the first quarter of fiscal 2026 ended March 31, 20261 in this Earnings Press Release and a Shareholder Letter issued today and posted on the Company's Corporate Website . “We remain confident in our strategy to build the industry-leading weight health platform.
The addition of Ozempic® pill will give Weight Watchers Med+ members a new FDA-approved oral GLP-1 option for adults living with type 2 diabetes The addition of Ozempic® pill will give Weight Watchers Med+ members a new FDA-approved oral GLP-1 option for adults living with type 2 diabetes
On April 30, 2026, Eli Lilly and Co (LLY) released its 8-K filing detailing first-quarter 2026 results. Revenue rose 56% year over year to $19.8 billion as stro
NEW YORK, April 27, 2026 (GLOBE NEWSWIRE) -- WW International, Inc. (NASDAQ: WW) (“Weight Watchers” or the “Company”), the global leader in science-backed weight management, today announced that it intends to utilize up to $40 million in cash to prepay and reduce the principal amount of its outstanding term loan.
NEW YORK, April 23, 2026 (GLOBE NEWSWIRE) -- WW International, Inc. (NASDAQ: WW) (“Weight Watchers” or the “Company”) will release its results for the first quarter 2026 ended March 31, 2026, before market open on Thursday, May 7, 2026.
NEW YORK, April 20, 2026 (GLOBE NEWSWIRE) -- WW International, Inc. (Nasdaq: WW) ("Weight Watchers" or the "Company"), the global leader in science-backed weight management, today announced that it has appointed Heather Thiltgen to the Company's Board of Directors, effective April 20, 2026.
NEW YORK, April 20, 2026 (GLOBE NEWSWIRE) -- WW International, Inc. (Nasdaq: WW) (“Weight Watchers” or the “Company”), the global leader in science-backed weight management, today announced that it has appointed Heather Thiltgen to the Company's Board of Directors, effective April 20, 2026. Ms. Thiltgen currently serves as the President of Presbyterian Health Plan and previously served as President & CEO of WellSense Health Plan.
NEW YORK, April 09, 2026 (GLOBE NEWSWIRE) -- WW International, Inc. (NASDAQ: WW) ("Weight Watchers"), the global leader in science-backed weight management, announced that it is now offering access to Eli Lilly and Company's newly FDA-approved oral GLP-1, Foundayo (orforglipron) through its Medoffering and affiliated medical groups.
NEW YORK, April 09, 2026 (GLOBE NEWSWIRE) -- WW International, Inc. (Nasdaq: WW) (“Weight Watchers” or the “Company”), the global leader in science-backed weight management, today announced the following updates to the composition of its Board of Directors' standing committees following the appointments of Lisa Gavales and Sue Gove as independent directors: Audit Committee: Gene Davis (Chair), Sue Gove, Carney Hawks and Nikolaj Sjoqvist; Compensation and Benefits Committee: Carney Hawks (Chair), Gene Davis and Lisa Gavales; Nominating and Corporate Governance Committee: Nikolaj Sjoqvist (Chair), Gene Davis and Sue Gove; and Strategy and Finance Committee: Gene Davis (Chair), Lisa Gavales, Carney Hawks, Mike Mason and Nikolaj Sjoqvist. Office of the CEO Update As previously announced, the Board established a Transition Committee to oversee the Office of the CEO, which comprises Felicia DellaFortuna, the Company's Chief Financial Officer, and Jon Volkmann, the Company's Chief Operations Officer.
New, Independent Directors Bring Deep Consumer, Digital and Turnaround Expertise to Support Strategic Transformation New, Independent Directors Bring Deep Consumer, Digital and Turnaround Expertise to Support Strategic Transformation
Office of the CEO Established to Oversee Business Operations Board Forms Transition Committee and Commences CEO Search NEW YORK, April 03, 2026 (GLOBE NEWSWIRE) -- WW International, Inc. (Nasdaq: WW) (“Weight Watchers” or the “Company”), the global leader in science-backed weight management, today announced leadership and governance changes, including the establishment of an Office of the CEO and the formation of a new Transition Committee of the Board of Directors (“the Board”). These actions follow Tara Comonte's departure from the Company, effective March 31, 2026.
Through expanded collaboration with Novo Nordisk, eligible Med+ members can now save up to $1,200 per year on Wegovy®, increasing affordable access to FDA-approved GLP-1 treatment leveraging Weight Watchers' integrated care platform Through expanded collaboration with Novo Nordisk, eligible Med+ members can now save up to $1,200 per year on Wegovy®, increasing affordable access to FDA-approved GLP-1 treatment leveraging Weight Watchers' integrated care platform
WW International, Inc. (WGHTQ) Q4 2025 Earnings Call Transcript
WW International (NASDAQ:WW), the global weight management company formerly known as Weight Watchers, released its fourth quarter and full-year 2025 financial results, showing stronger-than-expected earnings despite a year-over-year decline in total revenue. The company's shares surged more than 12% following the report, trading just shy of $24 on Monday morning.
2025 Total Revenue and Adjusted EBITDA 1,2 above high end of previously provided guidance Total End of Period Subscribers of 2.8 million; End of Period Clinical Subscribers of 130 thousand, up 42% year-over-year with continued growth in first quarter 2026 Fourth Quarter Total Revenue of $163 million; Clinical Subscription Revenue of $27 million, up 32% year-over-year Fourth Quarter Net Loss of $6 million; Net Loss Margin of 3.6%; Adjusted EBITDA 1 of $18 million and Adjusted EBITDA Margin 1 of 11.1% Provides First Quarter 2026 End of Period Subscriber Estimates and Full Year 2026 Financial Guidance NEW YORK, March 16, 2026 (GLOBE NEWSWIRE) -- WW International, Inc. (Nasdaq: WW) (“Weight Watchers” or the “Company”), the global leader in science-backed weight management, today announced its results for the fourth quarter and full year fiscal 2025 ended December 31, 2025 2 in this Earnings Press Release and a Shareholder Letter posted on the Company's Corporate Website . “Our industry is undergoing a profound transformation driven by GLP-1 medications, and Weight Watchers is evolving alongside it,” said Tara Comonte, CEO of Weight Watchers.
